# Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

> **NCT06055621** · PHASE2 · RECRUITING · sponsor: **Institut Paoli-Calmettes** · enrollment: 35 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT06055621
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-22
- **Primary completion:** 2026-07-08
- **Final completion:** 2027-10-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055621, "Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06055621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*